<DOC>
	<DOCNO>NCT00270348</DOCNO>
	<brief_summary>The primary objective determine CIC 50 mg/day 200 mg/day ( ex-valve ) administer daily morning non-inferior placebo respect growth velocity child mild persistent asthma follow 12-month treatment period The secondary objective investigate change growth term bone age ( wrist X-ray ) , maintenance asthma control safety ciclesonide</brief_summary>
	<brief_title>Effects Ciclesonide MDI 50mg/Day 200mg/Day ( Ex-Valve ) Once-Daily Growth Children With Mild Persistent Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Ciclesonide</mesh_term>
	<criteria>Females 5 7.5 year male 5 8.5 year age normal height , history mild persistent asthma least 3 month prior visit 1 , force expiratory volume one second ( FEV1 ) ³80 % predict follow least 4hour albuterol withhold , treat noncorticosteroid asthma medication asneeded daily basis , low dos inhale corticosteroid ( ICSs ) least one month prior Visit 1 . Subjects great Stage 1 Tanner classification sexual maturity , able demonstrate effective use MDI device perform reproducible pulmonary function test . Subjects history lifethreatening asthma , severe respiratory impairment , history abnormal growth , concurrent disease condition may substantially affect growth , previous requirement daily alternate day oral corticosteroid ( OCS ) treatment ³60 day within 2 year Visit 3 and/or use OCS within 30 day prior Visit 1 runin period , previous treatment moderate high dos inhale corticosteroid 30 day prior Visit 1</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>102 Months</maximum_age>
	<verification_date>December 2005</verification_date>
	<keyword>Asthma</keyword>
	<keyword>Safety</keyword>
	<keyword>Pediatrics</keyword>
</DOC>